Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Regulatory explorer
Regulatory document

FDA Notice: Availability of Final Guidance on New Dietary Ingredient Notifications

A Federal Register notice records that the FDA announced the availability of a final guidance for industry on new dietary ingredient notifications, covering identity and safety information for manufacturers and distributors. The record is an informational rendition, not the legal edition. [1]

Automatic summary · not editorially reviewed

The key findings

  1. The FDA announced the availability of a final guidance for industry on new dietary ingredient notifications. [1]

  2. The record is an informational rendition, not the official legal edition. [1]

  3. The guidance is intended to give recommendations to manufacturers and distributors on identity and safety information in notifications. [1]

The source at a glance

Jurisdiction
US
Authority
Health and Human Services Department; Food and Drug Administration
Document type
Notice
Record type / format
Notice (Federal Register document record)
Scope / context
Manufacturers and distributors of new dietary ingredients and of dietary supplements containing such an ingredient, as addressed in the agency abstract.
Summary based on
Official regulatory document
Original publication
October 20, 2026

FDA notice on final NDI guidance availability

This is a United States notice from the Department of Health and Human Services and the Food and Drug Administration, published on 2026-10-20. The agency announces the availability of a final guidance for industry titled "New Dietary Ingredient (NDI) Notifications and Related Issues; Identity and Safety Information About the NDI: Guidance for Industry." The document type is a notice, not a rule. The publication date is not necessarily an effective date.

Supporting source [1]

Who the guidance addresses and what it covers

According to the agency abstract, the guidance focuses on frequently asked questions about new dietary ingredient notification submissions. It is intended to help provide recommendations to manufacturers and distributors of new dietary ingredients and of dietary supplements containing such an ingredient. The stated subject is the identity and safety information that should be included in a notification. The abstract does not describe specific recommendations or their content.

Supporting source [1]

Informational rendition and status of this record

The web and API rendition is described as an informational resource, not the official legal edition. Readers are directed to verify the linked official PDF on GovInfo and applicable later amendments before relying on legal requirements. This source alone does not determine a product's compliance or current legal status. A notice is not a final rule, and a proposed rule or notice is not a final rule.

Supporting source [1]

How to interpret this

Document summary; not a determination of current law. Based only on the agency abstract and metadata; the full guidance text was not reviewed. The web/API rendition is informational; the linked official PDF on GovInfo is the legal edition. A publication date is not necessarily an effective date.

Based on the cited official document. Its jurisdiction, document type and effective date matter; a proposal or notice is not a rule already in force.

Source & supporting passages

[1]
New Dietary Ingredient (NDI) Notifications and Related Issues; Identity and Safety Information About the NDI: Guidance for Industry; Availability

Health and Human Services Department; Food and Drug Administration · federalregister.gov · October 20, 2026

Read the quoted passagesIn the language of the original source
  1. Finding 1 ↑

    announcing the availability of a final guidance
  2. Finding 2 ↑

    informational resource, not the official legal edition
  3. Finding 3 ↑

    recommendations to manufacturers and distributors of NDIs

AI-assisted summary with linked source passages. No independent editorial or clinical review.

Our editorial method

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…